54 Patients who were age and VASI score matched with combination group and usedNB-UVB were chosen as a control group
3 discontinued treatment by month 4(lost to follow-up)
49 patients were included efficacy analysis in month 3
9 discontinued treatment by month 3 5 patients withdrawal 4 lost to follow-up
43 patients included in efficacy analysis at month 4
35 patients included in efficacy analysis at month 6
4 discontinued treatment by month 4
Less than 3 months of treatment was excluded(n=5)
42 patients included in efficacy analysis at month 4
63 Patients with vitiligo treated with Baritinib plus NB- UVB in 2020 to 2023 were screened for eligibility
40 patients included in efficacy analysis at month 5
Less than 3 months of treatment was excluded(n=11)
38 patients included in efficacy analysis at month 5 to month 6
52 patients were included efficacy analysis in month 3
5 discontinued treatment by month 5 3 lost to follow-up 2 patients withdrawal
7 discontinued treatment by month 3 6 patients withdrawal 1 lost to follow-up
